This Week in European MedTech and HealthTech: 6th March 2026

vThis Week in European MedTech and HealthTech: 6th March 2026

This Week in European HealthTech: 6th March  2026

EU policy and regulation

The European Commission has tabled a new “Health Package” that includes the first phase of an EU Biotech Act plus targeted amendments to the Clinical Trials Regulation to speed set‑up and boost Europe’s competitiveness in life sciences.​

As part of the same package, proposed revisions to MDR/IVDR would remove the fixed five‑year certificate validity cap and move to risk‑based surveillance, aimed at reducing administrative burden and improving predictability for device and IVD manufacturers.​

The revision also hard‑wires cybersecurity into MDR/IVDR, obliging manufacturers to report actively exploited vulnerabilities and severe cyber incidents affecting medical devices within 30 days, aligned with wider EU cyber frameworks.

EU‑level work continues on integrating AI Act obligations with MDR/IVDR so that high‑risk medical AI can go through a single sectoral conformity route rather than duplicated certification, with most AI Act core obligations due to apply by August 2026.​

In parallel, the EU HTA Regulation machinery is now live, with initial joint clinical assessments already underway and more technologies, including MedTech, expected to enter the pipeline in 2026, setting the tone for future market access dossiers.​

Digital health and AI ecosystem

Policy discussions this week are heavily focused on whether EU health policy can keep pace with the AI wave in care delivery and diagnostics, with AI governance in health a central topic at industry fora such as “Masters of Digital 2026”.​

Recent analysis highlights that countries with well‑developed electronic health records and interoperable platforms are better positioned to scale teleconsultations and other virtual care models, keeping infrastructure and data interoperability high on national agendas.​

European‑level events like Athens Digital Health Week 2026 and the upcoming European Digital HealthTech Conference are being used to coordinate around EHDS implementation, regulatory issues for SaMD/AI, and adoption of digital medical devices in routine care.

Funding, grants and public money

Global Health EDCTP3 has opened its 2026 calls with up to €147m available across six topics, funding R&I on TB, lower respiratory tract infections, HIV (including co‑morbidities), and climate‑linked infectious disease, all of which have clear digital/clinical innovation angles.​

Within the wider Horizon Europe 2026–2027 work programme, a significant slice of a €14bn R&I envelope is earmarked for health and digital technologies, reinforcing medium‑term grant support for AI‑, data‑ and platform‑driven health innovation.​

Europe’s digital health investment landscape is being framed as entering a “proof through exits” phase in 2026, after leading global growth in 2025, with scrutiny shifting from round size to scalability, regulatory readiness and path to liquidity.​

Market and infrastructure signals

Analysis of European digital health maturity underlines large variance in teleconsultation share and EHR access across member states, with WHO experts reiterating that robust EHR infrastructure is a prerequisite for scaling digital health services.​

EU‑level efforts such as All Digital Weeks (9–25 March 2026) are being used to push digital skills and literacy, which are increasingly seen as enablers for adoption of patient‑facing and clinician‑facing digital health tools.​

Continued clarification of MDR/IVDR, EUDAMED roll‑out, and AI Act timelines is expected to shift MedTech/HealthTech focus from “regulatory uncertainty risk” towards execution on scale‑up and cross‑border deployment over the next 18–24 months.

What this likely means for deals

Near term, the Health Package proposals around MDR/IVDR and biotech/clinical trials should ease regulatory risk in diligence, but also harden expectations around cybersecurity and AI governance in targets’ product roadmaps.

The EDCTP3 and Horizon Europe envelopes create non‑dilutive capital for infectious‑disease‑linked platforms and data/AI‑heavy solutions, which may support pipeline building for future M&A rather than immediate large rounds.

With EU HTA structures and AI Act timelines clearer, assets positioned as “AI‑enabled devices/diagnostics” will be judged more on HTA‑ready evidence packages and integrated quality systems than on novelty of algorithms alone.

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk

>>>>

This Week in European MedTech: 6th March  2026

MDR/IVDR and core EU regulatory moves

The Commission has advanced targeted revisions to MDR and IVDR as part of the 2026 Health Package, aiming to streamline processes and reduce burdens while maintaining safety; this includes adjustments to conformity assessment predictability and notified body oversight.

The amending regulation also further codifies the “Helsinki procedure” for consistent product qualification and device classification across member states, with expanded use of expert panels for borderline products and complex classifications.​

Digitalisation provisions would allow EU declarations of conformity and certain IFUs to be provided in digital form only, and require economic operators to submit MDR/IVDR information electronically with digital contact details registered in EUDAMED.​

EUDAMED’s next phase is on track: four core modules became fully functional in late 2025, triggering a six‑month transition; from 28 May 2026, manufacturers and other actors must comply with enhanced transparency and registration obligations under MDR/IVDR.

The Commission is collecting stakeholder feedback on the MDR/IVDR amendment proposal through an extended consultation window that began in January 2026, with first‑reading legislation not expected before late H1 2026.​

Innovation, safety and procurement agenda

On 16 March 2026, the Commission will host a high‑level conference in Brussels on “Medical Devices: Innovation and Patient Safety,” with sessions on predictability of conformity assessments, the role of expert panels in EU‑level clinical evidence, and operationalising guidance for breakthrough technologies.

New EU‑level rules and guidance on procurement are setting the stage for an overhaul in how hospitals buy MedTech and diagnostics, with a stronger emphasis on value‑based purchasing, lifecycle cost, and innovation, which will affect pricing power and tender strategies.​

The Commission continues to publish updated lists of harmonised standards for medical devices, with a January 2026 tranche adding further standards under MDR, which becomes a practical compliance lever for manufacturers re‑baselining technical documentation.​

Market pressure and operating environment

EU data highlighted in recent analysis show sustained pressure on MedTech innovation portfolios, with evidence of reduced pipelines, cancelled launches and some production exits from the EU market, driven largely by the cost and complexity of MDR/IVDR compliance.​

Regulatory roadmaps for 2026 emphasise MDR/IVDR milestones such as certificate renewals, PMCF expectations, closer PRRC oversight and notified‑body interpretation trends, all of which are shaping manufacturer resource allocation and go‑no‑go decisions.

Commentators warn that 2026–2027 could be a “perfect storm” as legacy devices rush to transition from MDD/AIMDD/IVDD to MDR/IVDR against finite notified‑body capacity, creating real risk of certification gaps and forced device withdrawals for late movers.

MedTech M&A and strategic reshaping

Bain’s 2026 MedTech M&A report notes that medtech deal value has rebounded above pre‑2023 levels, with a clear boom in portfolio reshaping as large strategics prune non‑core assets and double down on higher‑growth technology platforms.​

Broader European HealthTech/MedTech forecasts for 2026 point to “bigger cheques, fewer bets,” with deal activity concentrating in assets that combine scale, robust clinical validation and AI or data‑driven capabilities rather than pure revenue add‑ons.

Analysts expect consolidation to be driven partly by regulatory complexity, with hardware incumbents and large‑cap tech players acquiring software and data innovators to secure “compliance moats” and data sovereignty under the evolving EU regulatory stack.

International expansion and AI‑driven MedTech

At CES 2026, European AI‑driven MedTech companies showcased solutions geared towards US reimbursement alignment, institutional contracting and governance, signalling a continued push to scale outside Europe despite regulatory headwinds at home.​

The EU’s wider “Digital Omnibus” and AI‑related proposals, though still under negotiation, are designed to synchronise AI Act high‑risk obligations with MDR/IVDR and streamline overlapping cybersecurity and reporting rules, which will directly affect AI‑enabled devices.

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk